Shanghai Shyndec Pharmaceutical Co., Ltd. (600420.SH) Latest Company News

Oct 30, 2026, 08:37 UTC
Shanghai Shyndec Pharmaceutical reported first-nine-month 2026 revenue of CNY 5.585 billion, down 19.29% year over year, and net profit attributable to shareholders of CNY 311 million, down 61.18%.
Source:
- finance.sina.cn
Oct 30, 2026, 08:37 UTC
Shanghai Shyndec Pharmaceutical reported third-quarter 2026 revenue of CNY 1.645 billion, down 19.46% year over year, and net profit attributable to shareholders of CNY 35.3961 million, down 72.58%.
Source:
- finance.sina.cn
Oct 22, 2026, 08:35 UTC
The National Medical Products Administration approved Guoyao Modern's registration certificate for voglibose tablets in 0.2 mg and 0.3 mg strengths, deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Oct 22, 2026, 08:34 UTC
Guoyao Zhijun agreed to acquire the marketing authorization and related rights for 50 mg eperisone hydrochloride tablets from Shandong Jingwei for a total of RMB 10 million, including tax, payable in installments.
Source:
- finance.sina.cn
Oct 15, 2026, 08:28 UTC
China’s National Medical Products Administration approved a drug registration certificate for Shanghai Shyndec Pharmaceutical’s agomelatine tablets, a 25 mg chemical drug for treating adult depression.
Source:
- finance.sina.cn
Oct 14, 2026, 12:02 UTC
China National Medicines Modern announced that it expects attributable net profit for the first three quarters of 2026 to be 296 million to 326 million yuan, down 59.30% to 63.05% year over year, and adjusted net profit to be 261 million to 291 million yuan, down 60.62% to 64.68%.
Source:
- finance.sina.cn
Sep 29, 2026, 07:32 UTC
China National Medicines Modern Pharmaceutical received a drug registration certificate for brexpiprazole tablets from the National Medical Products Administration, adding three strengths of 0.25mg, 0.5mg and 1mg.
Source:
- finance.sina.cn
Sep 18, 2026, 08:12 UTC
Sinopharm Modern Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for tacrolimus ointment in 0.03% and 0.1% strengths for moderate-to-severe atopic dermatitis.
Source:
- finance.sina.cn
Aug 28, 2026, 07:33 UTC
China National Medicines Corporation Ltd. received a drug registration certificate approved and issued by the National Medical Products Administration for Brexpiprazole tablets, an oral atypical antipsychotic drug for the treatment of adult schizophrenia, specification 2mg, registration classification as chemical drug category 4, deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Aug 18, 2026, 10:09 UTC
China Resources Double Crane received a drug registration certificate from the National Medical Products Administration for lidocaine hydrochloride gel, which is deemed to have passed consistency evaluation.
Source:
- finance.sina.cn
Aug 18, 2026, 09:19 UTC
Da An Gene announced it obtained a medical device registration certificate from China's National Medical Products Administration for its human parainfluenza virus nucleic acid detection kit (fluorescent PCR method), valid until August 16, 2031.
Source:
- finance.sina.cn
Aug 18, 2026, 09:16 UTC
China National Medicines' subsidiary Guoyao Rongsheng received approval from the National Medical Products Administration for its vitamin B12 injection, adding a new specification and passing the consistency evaluation for generic drugs.
Source:
- finance.sina.cn
Jul 30, 2026, 09:19 UTC
China National Medicines Corporation Ltd. announced that its subsidiary Sinopharm Zhijun Pingshan received regulatory approval to become the marketing authorization holder of lactulose oral solution.
Source:
- finance.sina.cn

600420.SH

Shanghai Shyndec Pharmaceutical reported first-nine-month 2026 revenue of CNY 5.585 billion, down 19.29% year over year, and net profit attributable to shareholders of CNY 311 million, down 61.18%.

Shanghai Shyndec Pharmaceutical reported third-quarter 2026 revenue of CNY 1.645 billion, down 19.46% year over year, and net profit attributable to shareholders of CNY 35.3961 million, down 72.58%.

The National Medical Products Administration approved Guoyao Modern's registration certificate for voglibose tablets in 0.2 mg and 0.3 mg strengths, deemed to have passed consistency evaluation.

Guoyao Zhijun agreed to acquire the marketing authorization and related rights for 50 mg eperisone hydrochloride tablets from Shandong Jingwei for a total of RMB 10 million, including tax, payable in installments.

China’s National Medical Products Administration approved a drug registration certificate for Shanghai Shyndec Pharmaceutical’s agomelatine tablets, a 25 mg chemical drug for treating adult depression.

China National Medicines Modern announced that it expects attributable net profit for the first three quarters of 2026 to be 296 million to 326 million yuan, down 59.30% to 63.05% year over year, and adjusted net profit to be 261 million to 291 million yuan, down 60.62% to 64.68%.

China National Medicines Modern Pharmaceutical received a drug registration certificate for brexpiprazole tablets from the National Medical Products Administration, adding three strengths of 0.25mg, 0.5mg and 1mg.

Sinopharm Modern Pharmaceutical received a drug registration certificate from China's National Medical Products Administration for tacrolimus ointment in 0.03% and 0.1% strengths for moderate-to-severe atopic dermatitis.

China Resources Double Crane received a drug registration certificate from the National Medical Products Administration for lidocaine hydrochloride gel, which is deemed to have passed consistency evaluation.

Da An Gene announced it obtained a medical device registration certificate from China's National Medical Products Administration for its human parainfluenza virus nucleic acid detection kit (fluorescent PCR method), valid until August 16, 2031.

China National Medicines' subsidiary Guoyao Rongsheng received approval from the National Medical Products Administration for its vitamin B12 injection, adding a new specification and passing the consistency evaluation for generic drugs.

China National Medicines Corporation Ltd. announced that its subsidiary Sinopharm Zhijun Pingshan received regulatory approval to become the marketing authorization holder of lactulose oral solution.